서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 40 of 102

Issue DateTitle / Author(s) / CitationFileAltmetrics
2013-06
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
DOI
2013-10
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

Cortes, J.; Baselga, J.; Im, Y. -H.; Im, S. -A.; Pivot, X.; Ross, G.; Clark, E.; Knott, A.; Swain, S. M.

Annals of Oncology, Vol.24 No.10, pp.2630-2635

DOI
2014-04
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non-Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor A Meta-analysis

Lee, June-Koo; Hahn, Seokyung; Kim, Dong-Wan; Suh, Koung Jin; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Heo, Dae Seog

JAMA - Journal of the American Medical Association, Vol.311 No.14, pp.1430-1437

DOI
2014-08
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

Kang, Y-K; Rha, S. Y.; Tassone, P.; Barriuso, J.; Yu, R.; Szado, T.; Garg, A.; Bang, Y-J

British Journal of Cancer, Vol.111 No.4, pp.660-666

DOI
2014-09
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
DOI
2015-03
Treatment for unresectable gastric cancer

Kim, Tae-Yong; Oh, Do-Youn; Bang, Yung-Jue

대한의사협회지, Vol.58 No.3, pp.209-215

DOI
2015-04
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
DOI
2015-08
Phase I/II study of weekly Oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer
DOI
2015-10
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
view fileDOI
2015-10
Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
DOI
2015-11
Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer
DOI
2015-12
Capecitabine for the treatment of gastric cancer

Kim, Tae-Yong; Oh, Do-Youn; Bang, Yung-Jue

Expert Review of Gastroenterology and Hepatology, Vol.9 No.12, pp.1471-1481

DOI
2016-02
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
view fileDOI
2016-03
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
DOI
2016-03
Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer
DOI
2016-04
Is there any role of adjuvant chemotherapy for T3N0M0 or T1N2M0 gastric cancer patients in stage II in the 7th TNM but stage I in the 6th TNM system?
DOI
2016-07
A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors
DOI
2017-01
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
DOI
2017-02
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
view fileDOI
2017-02
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
DOI
2017-04
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
DOI
2017-04
Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [C-11] DASB PK-PD Study
DOI
2017-05
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma The METGastric Randomized Clinical Trial
DOI
2017-05
Molecular Testing of Lung Cancers
DOI
2017-06
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
DOI
2017-07
Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea
DOI
2017-08
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
DOI
2017-09
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy
DOI
2017-09
ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)
DOI
2017-10
Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer
DOI
2017-10
Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer
DOI
2017-12
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
DOI
2018-01
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
DOI
2018-03
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
DOI
2018-03
Phase III, Randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE
DOI
2018-03
Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer
DOI
2018-03
Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK plus non-small cell lung cancer
view fileDOI
2018-04
Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer
DOI
2018-04
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results
DOI
2018-05
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial
DOI
1 2 3